Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease.

Bovée DM, Visser WJ, Middel I, De Mik-van Egmond A, Greupink R, Masereeuw R, Russel FGM, Danser AHJ, Zietse R, Hoorn EJ.

J Am Soc Nephrol. 2020 Jan 29. pii: ASN.2019090905. doi: 10.1681/ASN.2019090905. [Epub ahead of print]

PMID:
31996411
2.

Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.

Freriksen JJM, Schalkwijk S, Colbers AP, Abduljalil K, Russel FGM, Burger DM, Greupink R.

Clin Pharmacol Ther. 2019 Dec 23. doi: 10.1002/cpt.1748. [Epub ahead of print]

PMID:
31868223
3.

Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child.

Freriksen JJM, van Seyen M, Judd A, Gibb DM, Collins IJ, Greupink R, Russel FGM, Drenth JPH, Colbers A, Burger DM.

Aliment Pharmacol Ther. 2019 Oct;50(7):738-750. doi: 10.1111/apt.15476. Epub 2019 Aug 25. Review.

4.

Differential effects of psychoactive substances on human wildtype and polymorphic T356M dopamine transporters (DAT).

Zwartsen A, Litjens CHC, Hondebrink L, van den Heuvel JJMW, Greupink R, Russel FGM, de Lange DW, Legler J, Koenderink JB, Westerink RHS.

Toxicology. 2019 Jun 15;422:69-75. doi: 10.1016/j.tox.2019.04.012. Epub 2019 Apr 19.

5.

Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.

Schalkwijk S, Ter Heine R, Colbers A, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Moltó J, Mirochnick M, Karlsson MO, Burger DM.

J Antimicrob Chemother. 2019 May 1;74(5):1348-1356. doi: 10.1093/jac/dky567.

6.

Uremic solutes modulate hepatic bile acid handling and induce mitochondrial toxicity.

Weigand KM, Schirris TJJ, Houweling M, van den Heuvel JJMW, Koenderink JB, Dankers ACA, Russel FGM, Greupink R.

Toxicol In Vitro. 2019 Apr;56:52-61. doi: 10.1016/j.tiv.2019.01.003. Epub 2019 Jan 9.

7.

Experimental study of diclofenac and its biliary metabolites on anastomotic healing.

Yauw STK, Lomme RMLM, van den Broek P, Greupink R, Russel FGM, van Goor H.

BJS Open. 2018 May 17;2(4):220-228. doi: 10.1002/bjs5.63. eCollection 2018 Aug.

8.

Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.

van der Galiën R, Ter Heine R, Greupink R, Schalkwijk SJ, van Herwaarden AE, Colbers A, Burger DM.

Clin Pharmacokinet. 2019 Mar;58(3):309-323. doi: 10.1007/s40262-018-0684-z. Review.

9.

Placental disposition of the immunosuppressive drug tacrolimus in renal transplant recipients and in ex vivo perfused placental tissue.

Freriksen JJM, Feyaerts D, van den Broek PHH, van der Heijden OWH, van Drongelen J, van Hamersvelt HW, Russel FGM, van der Molen RG, Greupink R.

Eur J Pharm Sci. 2018 Jul 1;119:244-248. doi: 10.1016/j.ejps.2018.04.017. Epub 2018 Apr 12.

10.

Corrigendum to 'Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs' [European Journal of Pharmaceutical Sciences 115 (2018) 175-184].

Notenboom S, Weigand KM, Proost JH, van Lipzig MM, van de Steeg E, van den Broek PHH, Greupink R, Russel FGM, Groothuis GMM.

Eur J Pharm Sci. 2018 May 30;117:392-393. doi: 10.1016/j.ejps.2018.04.005. No abstract available.

PMID:
29650218
11.

Microbial Glucuronidase Inhibition Reduces Severity of Diclofenac-Induced Anastomotic Leak in Rats.

Yauw STK, Arron M, Lomme RMLM, van den Broek P, Greupink R, Bhatt AP, Redinbo MR, van Goor H.

Surg Infect (Larchmt). 2018 May/Jun;19(4):417-423. doi: 10.1089/sur.2017.245. Epub 2018 Apr 6.

12.

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.

Schalkwijk S, Ter Heine R, Colbers AC, Huitema ADR, Denti P, Dooley KE, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Mirochnick M, Burger DM.

Clin Pharmacokinet. 2018 Nov;57(11):1421-1433. doi: 10.1007/s40262-018-0642-9.

13.

Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations.

Ke AB, Greupink R, Abduljalil K.

CPT Pharmacometrics Syst Pharmacol. 2018 Feb;7(2):103-110. doi: 10.1002/psp4.12274. Epub 2018 Jan 31. Review.

14.

Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs.

Notenboom S, Weigand KM, Proost JH, van Lipzig MMH, van de Steeg E, van den Broek PHH, Greupink R, Russel FGM, Groothuis GMM.

Eur J Pharm Sci. 2018 Mar 30;115:175-184. doi: 10.1016/j.ejps.2018.01.007. Epub 2018 Jan 5. Erratum in: Eur J Pharm Sci. 2018 May 30;117:392-393.

15.

Free dug concentrations in pregnancy: Bound to measure unbound?

Schalkwijk S, Greupink R, Burger D.

Br J Clin Pharmacol. 2017 Dec;83(12):2595-2598. doi: 10.1111/bcp.13432. Epub 2017 Oct 6. No abstract available.

16.

Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease.

de Haas R, Das D, Garanto A, Renkema HG, Greupink R, van den Broek P, Pertijs J, Collin RWJ, Willems P, Beyrath J, Heerschap A, Russel FG, Smeitink JA.

Sci Rep. 2017 Sep 15;7(1):11733. doi: 10.1038/s41598-017-09417-5.

17.

Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.

Schalkwijk S, Buaben AO, Freriksen JJM, Colbers AP, Burger DM, Greupink R, Russel FGM.

Clin Pharmacokinet. 2018 Jun;57(6):705-716. doi: 10.1007/s40262-017-0583-8.

18.

Rat precision-cut liver slices predict drug-induced cholestatic injury.

Starokozhko V, Greupink R, van de Broek P, Soliman N, Ghimire S, de Graaf IAM, Groothuis GMM.

Arch Toxicol. 2017 Oct;91(10):3403-3413. doi: 10.1007/s00204-017-1960-7. Epub 2017 Apr 8.

19.

Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon.

Eliesen GAM, van den Broek P, van den Heuvel JJ, Bilos A, Pertijs J, van Drongelen J, Russel FGM, Greupink R.

Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.

PMID:
28369651
20.

Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman.

Schalkwijk S, Feiterna-Sperling C, Weizsäcker K, Colbers A, Bührer C, Greupink R, Russel FG, Burger D; PANNA network.

AIDS. 2016 Jul 31;30(12):1999-2001. doi: 10.1097/QAD.0000000000001123. No abstract available.

PMID:
27428578
21.

First reported use of elvitegravir and cobicistat during pregnancy.

Schalkwijk S, Colbers A, Konopnicki D, Greupink R, Russel FG, Burger D; PANNA network.

AIDS. 2016 Mar 13;30(5):807-8. doi: 10.1097/QAD.0000000000000976. No abstract available.

PMID:
26913711
22.

Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model.

Schalkwijk S, Greupink R, Colbers AP, Wouterse AC, Verweij VG, van Drongelen J, Teulen M, van den Oetelaar D, Burger DM, Russel FG.

J Antimicrob Chemother. 2016 Feb;71(2):480-3. doi: 10.1093/jac/dkv358. Epub 2015 Nov 3.

PMID:
26538508
23.

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

Colbers A, Greupink R, Litjens C, Burger D, Russel FG.

Clin Pharmacokinet. 2016 Mar;55(3):381-96. doi: 10.1007/s40262-015-0325-8.

24.

Convallatoxin: a new P-glycoprotein substrate.

Gozalpour E, Greupink R, Bilos A, Verweij V, van den Heuvel JJ, Masereeuw R, Russel FG, Koenderink JB.

Eur J Pharmacol. 2014 Dec 5;744:18-27. doi: 10.1016/j.ejphar.2014.09.031. Epub 2014 Sep 28.

PMID:
25264938
25.

Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.

Gozalpour E, Greupink R, Wortelboer HM, Bilos A, Schreurs M, Russel FG, Koenderink JB.

Mol Pharm. 2014 Jun 2;11(6):1844-55. doi: 10.1021/mp400699p. Epub 2014 May 6.

PMID:
24754247
26.

In silico identification and in vitro validation of potential cholestatic compounds through 3D ligand-based pharmacophore modeling of BSEP inhibitors.

Ritschel T, Hermans SM, Schreurs M, van den Heuvel JJ, Koenderink JB, Greupink R, Russel FG.

Chem Res Toxicol. 2014 May 19;27(5):873-81. doi: 10.1021/tx5000393. Epub 2014 Apr 23.

PMID:
24713091
27.

Pharmacological considerations on the use of antiretrovirals in pregnancy.

Colbers A, Greupink R, Burger D.

Curr Opin Infect Dis. 2013 Dec;26(6):575-88. doi: 10.1097/QCO.0000000000000017. Review.

PMID:
24152762
28.

Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4.

El-Sheikh AA, Greupink R, Wortelboer HM, van den Heuvel JJ, Schreurs M, Koenderink JB, Masereeuw R, Russel FG.

Transl Res. 2013 Dec;162(6):398-409. doi: 10.1016/j.trsl.2013.08.003. Epub 2013 Sep 12.

PMID:
24036158
29.

Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.

Greupink R, Schreurs M, Benne MS, Huisman MT, Russel FG.

Eur J Pharm Sci. 2013 Aug 16;49(5):819-28. doi: 10.1016/j.ejps.2013.06.009. Epub 2013 Jun 24.

PMID:
23806476
30.

Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1.

van de Steeg E, Greupink R, Schreurs M, Nooijen IH, Verhoeckx KC, Hanemaaijer R, Ripken D, Monshouwer M, Vlaming ML, DeGroot J, Verwei M, Russel FG, Huisman MT, Wortelboer HM.

Drug Metab Dispos. 2013 Mar;41(3):592-601. doi: 10.1124/dmd.112.049023. Epub 2012 Dec 17.

PMID:
23248200
31.

Interaction of digitalis-like compounds with p-glycoprotein.

Gozalpour E, Wittgen HG, van den Heuvel JJ, Greupink R, Russel FG, Koenderink JB.

Toxicol Sci. 2013 Feb;131(2):502-11. doi: 10.1093/toxsci/kfs307. Epub 2012 Oct 26.

PMID:
23104431
32.

In silico identification of potential cholestasis-inducing agents via modeling of Na(+)-dependent taurocholate cotransporting polypeptide substrate specificity.

Greupink R, Nabuurs SB, Zarzycka B, Verweij V, Monshouwer M, Huisman MT, Russel FG.

Toxicol Sci. 2012 Sep;129(1):35-48. doi: 10.1093/toxsci/kfs188. Epub 2012 May 28.

PMID:
22641618
33.

Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists.

Wittgen HG, Greupink R, van den Heuvel JJ, van den Broek PH, Dinter-Heidorn H, Koenderink JB, Russel FG.

Mol Pharm. 2012 May 7;9(5):1351-60. doi: 10.1021/mp200617z. Epub 2012 Mar 28.

PMID:
22428727
34.

Interaction of fluvastatin with the liver-specific Na+ -dependent taurocholate cotransporting polypeptide (NTCP).

Greupink R, Dillen L, Monshouwer M, Huisman MT, Russel FG.

Eur J Pharm Sci. 2011 Nov 20;44(4):487-96. doi: 10.1016/j.ejps.2011.09.009. Epub 2011 Sep 16.

PMID:
21945488
35.

Evaluation of a 99mTc-labeled AnnexinA5 variant for non-invasive SPECT imaging of cell death in liver, spleen and prostate.

Greupink R, Sio CF, Ederveen A, Orsel J.

Pharm Res. 2009 Dec;26(12):2647-56. doi: 10.1007/s11095-009-9981-4. Epub 2009 Sep 25.

PMID:
19779967
36.

Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated.

Hagens WI, Mattos A, Greupink R, de Jager-Krikken A, Reker-Smit C, van Loenen-Weemaes A, Gouw IA, Poelstra K, Beljaars L.

Pharm Res. 2007 Mar;24(3):566-74.

37.

Pharmacokinetics of a hepatic stellate cell-targeted doxorubicin construct in bile duct-ligated rats.

Greupink R, Reker-Smit C, Proost JH, van Loenen Weemaes AM, de Hooge M, Poelstra K, Beljaars L.

Biochem Pharmacol. 2007 May 1;73(9):1455-62. Epub 2006 Dec 15.

PMID:
17239825
38.

Mannose-6-phosphate/insulin-Like growth factor-II receptors may represent a target for the selective delivery of mycophenolic acid to fibrogenic cells.

Greupink R, Bakker HI, van Goor H, de Borst MH, Beljaars L, Poelstra K.

Pharm Res. 2006 Aug;23(8):1827-34.

PMID:
16850269
39.

Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology.

Gonzalo T, Talman EG, van de Ven A, Temming K, Greupink R, Beljaars L, Reker-Smit C, Meijer DK, Molema G, Poelstra K, Kok RJ.

J Control Release. 2006 Mar 10;111(1-2):193-203. Epub 2006 Feb 7.

PMID:
16466667
40.

The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo.

Greupink R, Bakker HI, Bouma W, Reker-Smit C, Meijer DK, Beljaars L, Poelstra K.

J Pharmacol Exp Ther. 2006 May;317(2):514-21. Epub 2006 Jan 26.

PMID:
16439617
41.

Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell.

Greupink R, Bakker HI, Reker-Smit C, van Loenen-Weemaes AM, Kok RJ, Meijer DK, Beljaars L, Poelstra K.

J Hepatol. 2005 Nov;43(5):884-92. Epub 2005 Jun 4.

PMID:
16083988

Supplemental Content

Loading ...
Support Center